BTK inhibitorFDA-approvedSecond-line
Zanubrutinib
How it works
Blocks the BTK enzyme, which is overactive in certain leukemia cells, preventing them from multiplying.
Cancer types
Leukemia— All patients
Efficacy
In clinical trials, around 80% of patients with relapsed or refractory mantle cell lymphoma achieved a complete response, with a significant reduction in disease progression.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Zanubrutinib with Sonrotoclax for Untreated CLL/SLL | Leukemia | phase-3 | — | Source → |
| Testing Zanubrutinib and Obinutuzumab in Untreated CLL or SLL Patients | Leukemia | phase-2 | — | Source → |
| Testing Emavusertib with Zanubrutinib for CLL and Other B-cell Malignancies | Leukemia | phase-2 | — | Source → |
| Testing Zanubrutinib and Rituximab for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Leukemia | phase-2 | — | Source → |
| Zanubrutinib Shows Promise in Rare Blood Cancer | Leukemia | observational | — | Source → |
| Zanubrutinib and Sonrotoclax Combination for Rare Lymphoma in Underrepresented Groups | Leukemia | phase-1 | — | Source → |
| Investigating a New Treatment Combination for Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| New Treatment Combination for Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-3 | — | Source → |
| Zanubrutinib, Obinutuzumab, and Venetoclax for CLL or SLL | Leukemia | phase-2 | — | Source → |
| Study of CLL Treatment Combination | Leukemia | phase-3 | — | Source → |
| Comparing Zanubrutinib and Acalabrutinib in Relapsed CLL | Leukemia | phase-3 | One progression was avoided per 10 patients treated (NNT=10) and one death per 15 patients treated (NNT=15) with zanubrutinib. | Source → |
| New Study Compares Effectiveness of CLL Treatments | Leukemia | meta-analysis | Zanubrutinib had a significantly reduced risk of progression or death compared with ibrutinib (hazard ratio [HR], 0.49; 95% credible interval [CrI], 0.31-0.78). | Source → |
| Zanubrutinib vs Ibrutinib for Chronic Lymphocytic Leukemia: Cost Comparison | Leukemia | phase-3 | Treating 8 patients with zanubrutinib instead of ibrutinib prevented 1 progression or death. | Source → |
| Rare Side Effect of Cancer Drug Zanubrutinib | Leukemia | observational | — | Source → |
| Expert Panel Discusses Zanubrutinib Use in Chronic Lymphocytic Leukemia | Leukemia | review | — | Source → |
| Comparing Zanubrutinib and Ibrutinib for Leukemia Treatment | Leukemia | meta-analysis | — | Source → |
| New Mutation Found in CLL Patients on Zanubrutinib Treatment | Leukemia | lab-study | — | Source → |
| Zanubrutinib Monotherapy for CLL/SLL Shows Promising Results | Leukemia | phase-1/2 | The overall response rate was 95.4% and significantly higher in the treatment-naïve group than in the relapsed/refractory group (100 vs. 91.0%, p < 0.0001). | Source → |
| Zanubrutinib Safety in B-Cell Malignancy Patients | Leukemia | phase-2 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.